Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mutations01:39

Mutations

Overview
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient Engagement in the Implementation of Electronic Patient-Reported Outcome Tools: The Experience of Two Early-Adopter Institutions in the Pan-Canadian Radiotherapy Patient-Reported Outcome Initiative.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2024
Same author

Phenotyping Down syndrome: discovery and predictive modelling with electronic medical records.

Journal of intellectual disability research : JIDR·2024
Same author

Survival and Success Rates of Endodontically Treated Teeth Restored with Full Veneer Crowns or Full Cuspal Coverage onlays: A Systematic Review.

The European journal of prosthodontics and restorative dentistry·2023
Same author

<i>Reply</i>.

AJNR. American journal of neuroradiology·2022
Same author

Feasibility of delivering foot and ankle surgical courses in a partnership in Eastern, Central and Sothern Africa.

BMC medical education·2022

Related Experiment Video

Updated: Jul 6, 2026

A Non-random Mouse Model for Pharmacological Reactivation of Mecp2 on the Inactive X Chromosome
08:27

A Non-random Mouse Model for Pharmacological Reactivation of Mecp2 on the Inactive X Chromosome

Published on: May 22, 2019

Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome.

J L Neul1, P Fang, J Barrish

  • 1Section of Neurology, Department of Pediatrics, Baylor College of Medicine, Room 319C, One Baylor Plaza, Houston, TX 77030, USA. jneul@bcm.tmc.edu

Neurology
|March 14, 2008
PubMed
Summary

Specific mutations in the MECP2 gene influence the severity of Rett syndrome, impacting key features like ambulation and language. Understanding these genotype-phenotype correlations aids in targeted therapy development.

More Related Videos

An Electrochemiluminescence-Based Assay for MeCP2 Protein Variants
07:44

An Electrochemiluminescence-Based Assay for MeCP2 Protein Variants

Published on: May 22, 2020

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene
08:22

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene

Published on: September 16, 2019

Related Experiment Videos

Last Updated: Jul 6, 2026

A Non-random Mouse Model for Pharmacological Reactivation of Mecp2 on the Inactive X Chromosome
08:27

A Non-random Mouse Model for Pharmacological Reactivation of Mecp2 on the Inactive X Chromosome

Published on: May 22, 2019

An Electrochemiluminescence-Based Assay for MeCP2 Protein Variants
07:44

An Electrochemiluminescence-Based Assay for MeCP2 Protein Variants

Published on: May 22, 2020

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene
08:22

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene

Published on: September 16, 2019

Area of Science:

  • Genetics
  • Neurodevelopmental Disorders
  • Molecular Biology

Background:

  • Rett syndrome is a severe X-linked dominant neurodevelopmental disorder.
  • The methyl-CpG-binding protein 2 (MECP2) gene is frequently mutated in Rett syndrome patients.

Purpose of the Study:

  • To investigate the relationship between specific MECP2 gene mutations and the clinical presentation of Rett syndrome.
  • To correlate MECP2 mutation types with disease severity and specific clinical features.

Main Methods:

  • Cross-sectional study of 245 individuals with Rett syndrome.
  • Analysis of MECP2 mutation status and structured clinical evaluations.
  • Comparison of clinical features grouped by MECP2 mutation type.

Main Results:

  • MECP2 mutations R133C and R294X are associated with milder disease compared to R168X or large deletions.
  • Specific mutations correlate with differences in ambulation, hand use, and language abilities.
  • Carboxy-terminal truncating mutations are linked to better outcomes in ambulation and language.

Conclusions:

  • MECP2 mutation type significantly influences Rett syndrome severity.
  • Genotype-phenotype correlations are crucial for predicting disease trajectory.
  • Findings support the development of targeted therapies and informed clinical trial design.